



	Gravità:	Ins:	Doc.:	Numero:	Ass:
FELDENE	Maggiore	Non specificato	Discreta	335	124
SOLDESAM					
Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.					
BRUFEN	Maggiore	Ritardato	Buona	301	194
MODURETIC					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
BRUFEN	Maggiore	Non specificato	Buona	301	194
MODURETIC					
Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity.					
BRUFEN	Maggiore	Non specificato	Buona	246	136
CLEXANE					
Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding.					
BRUFEN	Maggiore	Non specificato	Discreta	225	149
COUMADIN					
Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding.					
CARDIOASPIRIN	Maggiore	Non specificato	Discreta	224	140
OKI					
La contemporanea assunzione di ASPIRINA e KETOPROFENE può portare ad un aumento del rischio di seri effetti avversi gastrointestinali (ulcera, sanguinamento, perforazione della mucosa).					
DELTACORTENE	Maggiore	Non specificato	Discreta	212	131
OKI					
Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.					
BRUFEN	Maggiore	Non specificato	Discreta	172	116
MEDROL					
Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.					
CARDIOASPIRIN	Maggiore	Non specificato	Discreta	153	97
VOLTAREN					
Concurrent use of ASPIRIN and DICLOFENAC may result in increased risk of bleeding.					
CLEXANE	Maggiore	Non specificato	Buona	153	105
ORUDIS					
Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding.					
DELTACORTENE	Maggiore	Non specificato	Discreta	138	97
DICLOREUM					
Concurrent use of CORTICOSTEROIDS and NSAIDS (SELECTED) may result in increased risk of gastrointestinal ulcer or bleeding.					
BRUFEN	Maggiore	Non specificato	Eccellente	135	97
LAROXYL					
Concurrent use of NSAID and TRICYCLIC ANTIDEPRESSANTS may result in an increased risk of bleeding.					
BRUFEN	Maggiore	Ritardato	Buona	129	51
VASORETIC					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
DELTACORTENE	Maggiore	Non specificato	Discreta	119	81
VOLTAREN					
Concurrent use of CORTICOSTEROIDS and NSAIDS (SELECTED) may result in increased risk of gastrointestinal ulcer or bleeding.					
CARDIOASPIRIN	Controindicato	Non specificato	Discreta	118	73
TORADOL					
Concurrent use of ASPIRIN and KETOROLAC may result in enhanced gastrointestinal adverse effects (peptic ulcers, gastrointestinal bleeding, and/or perforation) and possible increase in serum ketorolac levels.					
BRUFEN	Maggiore	Ritardato	Buona	112	72
OLPREZIDE					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
LASIX	Maggiore	Non specificato	Buona	112	61

Stat IF per farmaco (limitato alle prime 200 interazioni con maggior numero di occorrenze)

Pag. 1 di 13

Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX®.



Gravità:	Ins:	Doc.:	Numero:	Ass:
----------	------	-------	---------	------

TORADOL

Concurrent use of LOOP DIURETICS and NSAIDS may result in reduced diuretic effectiveness and possible nephrotoxicity.

BRUFEN	Controindicato	Nelle 24 ore	Discreta	111	83
---------------	----------------	--------------	----------	-----	----

TORADOL

La contemporanea assunzione di KETOROLAC e AGENTI ANTIINFIAMMATORI NON STEROIDEI può portare ad effetti avversi gastrointestinali seri (ulcere peptiche, emorragia e/o perforazione gastrointestinale).

CELEBREX	Maggiore	Non specificato	Discreta	104	56
-----------------	----------	-----------------	----------	-----	----

MEDROL

Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.

CLEXANE	Maggiore	Non specificato	Buona	104	44
----------------	----------	-----------------	-------	-----	----

TORADOL

Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding.

MODURETIC	Maggiore	Ritardato	Buona	99	53
------------------	----------	-----------	-------	----	----

VOLTAREN

Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.

MODURETIC	Maggiore	Non specificato	Buona	99	53
------------------	----------	-----------------	-------	----	----

VOLTAREN

Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity.

BRUFEN	Maggiore	Non specificato	Eccellente	93	54
---------------	----------	-----------------	------------	----	----

CIPRALEX

Concurrent use of NSAID and SSRI may result in an increased risk of bleeding.

CELEBREX	Maggiore	Ritardato	Buona	93	44
-----------------	----------	-----------	-------	----	----

MODURETIC

Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.

BRUFEN	Maggiore	Ritardato	Buona	93	59
---------------	----------	-----------	-------	----	----

PLAUNAZIDE

Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.

CELEBREX	Maggiore	Non specificato	Buona	93	44
-----------------	----------	-----------------	-------	----	----

MODURETIC

Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity.

BRUFEN	Maggiore	Non specificato	Eccellente	92	49
---------------	----------	-----------------	------------	----	----

CYMBALTA

Concurrent use of NSAID and SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS may result in an increased risk of bleeding.

CLEXANE	Maggiore	Non specificato	Buona	91	45
----------------	----------	-----------------	-------	----	----

OKI

Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding.

DELTACORTENE	Maggiore	Non specificato	Discreta	90	64
---------------------	----------	-----------------	----------	----	----

ORUDIS

Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.

MODURETIC	Maggiore	Ritardato	Buona	88	64
------------------	----------	-----------	-------	----	----

OKI

Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.

MODURETIC	Maggiore	Non specificato	Buona	88	64
------------------	----------	-----------------	-------	----	----

OKI

Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity.

CARDIOASPIRIN	Maggiore	Non specificato	Discreta	87	60
----------------------	----------	-----------------	----------	----	----

ORUDIS

La contemporanea assunzione di ASPIRINA e KETOPROFENE può portare ad un aumento del rischio di seri effetti avversi gastrointestinali (ulcera, sanguinamento, perforazione della mucosa).



	Gravità:	Ins:	Doc.:	Numero:	Ass:
BRUFEN	Maggiore	Non specificato	Discreta	84	55
LANOXIN					
Concurrent use of DIGOXIN and IBUPROFEN may result in increased digoxin exposure.					
CELEBREX	Maggiore	Non specificato	Discreta	81	56
DELTACORTENE					
Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.					
MODURETIC	Maggiore	Ritardato	Buona	80	46
ORUDIS					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
MODURETIC	Maggiore	Non specificato	Buona	80	46
ORUDIS					
Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity.					
BRUFEN	Maggiore	Ritardato	Buona	79	29
METHOTREXATE					
La contemporanea assunzione di METOTREXATO e IBUPROFENE può determinare tossicità da metotrexato (leucopenia, trombocitopenia, anemia, nefrotossicità, ulcerazioni della mucosa).					
CARDIOASPIRIN	Maggiore	Non specificato	Discreta	76	61
DICLOREUM					
Concurrent use of ASPIRIN and DICLOFENAC may result in increased risk of bleeding.					
BRUFEN	Maggiore	Ritardato	Buona	76	31
REUMAFLEX					
La contemporanea assunzione di METOTREXATO e IBUPROFENE può determinare tossicità da metotrexato (leucopenia, trombocitopenia, anemia, nefrotossicità, ulcerazioni della mucosa).					
BENTELAN	Maggiore	Non specificato	Discreta	75	55
CELEBREX					
Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.					
BRUFEN	Maggiore	Ritardato	Buona	75	36
ZESTORETIC					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
BRUFEN	Maggiore	Non specificato	Eccellente	74	54
SEREUPIN					
Concurrent use of NSAID and SSRI may result in an increased risk of bleeding.					
BRUFEN	Maggiore	Non specificato	Buona	74	33
CLEXANE T					
Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding.					
CELEBREX	Maggiore	Ritardato	Buona	71	24
TRIATEC HCT					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
DICLOREUM	Maggiore	Ritardato	Buona	71	35
MODURETIC					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
DICLOREUM	Maggiore	Non specificato	Buona	71	35
MODURETIC					
Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity.					
BRUFEN	Maggiore	Non specificato	Discreta	69	36
TICLOPIDINA DOROM					
Concurrent use of ANTIPLATELET AGENTS and NSAIDS may result in increased risk of bleeding.					
CELEBREX	Maggiore	Ritardato	Discreta	68	22
REUMAFLEX					
Concurrent use of METHOTREXATE and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in increased methotrexate exposure.					



	Gravità:	Ins:	Doc.:	Numero:	Ass:
BRUFEN	Maggiore	Ritardato	Buona	67	45
MICARDISPLUS					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
COUMADIN	Maggiore	Non specificato	Discreta	66	38
OKI					
Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding.					
BRUFEN	Maggiore	Non specificato	Discreta	62	33
SYMBICORT					
Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.					
CELEBREX	Maggiore	Non specificato	Discreta	62	33
COUMADIN					
Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding.					
CARDIOASPIRIN	Maggiore	Non specificato	Discreta	61	44
FELDENE					
Concurrent use of ASPIRIN and NSAIDS may result in increased risk of bleeding.					
BRUFEN	Maggiore	Ritardato	Buona	60	41
LODOZ					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
LAROXYL	Maggiore	Non specificato	Eccellente	59	34
OKI					
Concurrent use of NSAID and TRICYCLIC ANTIDEPRESSANTS may result in an increased risk of bleeding.					
BRUFEN	Maggiore	Non specificato	Buona	58	28
DIURESIX					
Concurrent use of LOOP DIURETICS and NSAIDS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
CELEBREX	Maggiore	Non specificato	Buona	57	30
CLEXANE					
Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding.					
MODURETIC	Maggiore	Ritardato	Buona	57	29
TORADOL					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
BLOPRESID	Maggiore	Ritardato	Buona	57	37
BRUFEN					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
MODURETIC	Maggiore	Non specificato	Buona	57	29
TORADOL					
Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity.					
BRUFEN	Maggiore	Ritardato	Buona	55	32
LOBIDIUR					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
FELDENE	Maggiore	Non specificato	Buona	55	34
LASIX					
Concurrent use of LOOP DIURETICS and NSAIDS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
VASORETIC	Maggiore	Ritardato	Buona	54	23
VOLTAREN					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
BRUFEN	Maggiore	Non specificato	Eccellente	53	38
ENTACT					
Concurrent use of NSAID and SSRI may result in an increased risk of bleeding.					
ARTROSILENE	Maggiore	Non specificato	Discreta	53	36
CARDIOASPIRIN					



Gravità:	Ins:	Doc.:	Numero:	Ass:
----------	------	-------	---------	------

La contemporanea assunzione di ASPIRINA e KETOPROFENE può portare ad un aumento del rischio di seri effetti avversi gastrointestinali (ulcera, sanguinamento, perforazione della mucosa).

BRUFEN	Maggiore	Ritardato	Buona	51	26
PRITORPLUS					

Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.

BRUFEN	Maggiore	Non specificato	Eccellente	51	21
EFEXOR					

Concurrent use of NSAID and SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS may result in an increased risk of bleeding.

LAROXYL	Maggiore	Non specificato	Eccellente	51	32
TORADOL					

Concurrent use of NSAID and TRICYCLIC ANTIDEPRESSANTS may result in an increased risk of bleeding.

BRUFEN	Maggiore	Ritardato	Buona	50	25
ESIDREX					

Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.

BRUFEN	Maggiore	Non specificato	Discreta	50	43
CELEBREX					

Concurrent use of NSAIDS and NSAIDS AND SALICYLATES may result in increased risk of bleeding.

DELTACORTENE	Maggiore	Non specificato	Discreta	49	41
KETOPROFENE DOC					

Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.

CARDIOASPIRIN	Maggiore	Non specificato	Discreta	49	33
DICLOFENAC EG					

Concurrent use of ASPIRIN and DICLOFENAC may result in increased risk of bleeding.

CLEXANE	Maggiore	Non specificato	Buona	49	31
VOLTAREN					

Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding.

CELEBREX	Maggiore	Ritardato	Discreta	49	19
METHOTREXATE					

Concurrent use of METHOTREXATE and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in increased methotrexate exposure.

MEDROL	Maggiore	Non specificato	Discreta	47	28
TORADOL					

Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.

CLEXANE T	Maggiore	Non specificato	Buona	47	18
TORADOL					

Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding.

BIFRIZIDE	Maggiore	Ritardato	Buona	47	31
BRUFEN					

Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.

BRUFEN	Maggiore	Non specificato	Eccellente	46	27
DAPAROX					

Concurrent use of NSAID and SSRI may result in an increased risk of bleeding.

DELTACORTENE	Maggiore	Non specificato	Discreta	45	33
DICLOFENAC EG					

Concurrent use of CORTICOSTEROIDS and NSAIDS (SELECTED) may result in increased risk of gastrointestinal ulcer or bleeding.

FELDENE	Maggiore	Ritardato	Buona	45	5
VASORETIC					

Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.

MEDROL	Maggiore	Non specificato	Discreta	44	33
VOLTAREN					



	Gravità:	Ins:	Doc.:	Numero:	Ass:
Concurrent use of CORTICOSTEROIDS and NSAIDS (SELECTED) may result in increased risk of gastrointestinal ulcer or bleeding.					
CARDIOASPIRIN	Maggiore	Non specificato	Discreta	43	23
INDOXEN					
Concurrent use of ASPIRIN and NSAIDS may result in increased risk of bleeding.					
DICLOFENAC EG	Maggiore	Ritardato	Buona	42	22
MODURETIC					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
DICLOFENAC EG	Maggiore	Non specificato	Buona	42	22
MODURETIC					
Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity.					
OKI	Controindicato	Nelle 24 ore	Discreta	42	27
TORADOL					
Concurrent use of KETOROLAC and NSAIDS may result in enhanced gastrointestinal adverse effects (peptic ulcers, gastrointestinal bleeding and/or perforation).					
TORADOL	Controindicato	Nelle 24 ore	Discreta	41	24
VOLTAREN					
La contemporanea assunzione di KETOROLAC e AGENTI ANTIINFAMMATORI NON STEROIDEI può portare ad effetti avversi gastrointestinali seri (ulcere peptiche, emorragia e/o perforazione gastrointestinale).					
CYMBALTA	Maggiore	Non specificato	Eccellente	40	15
TORADOL					
Concurrent use of NSAID and SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS may result in an increased risk of bleeding.					
CELECOXIB TEVA	Maggiore	Non specificato	Discreta	40	35
REUMAGIL					
Concurrent use of NSAIDS and NSAIDS AND SALICYLATES may result in increased risk of bleeding.					
BRUFEN	Maggiore	Non specificato	Eccellente	39	26
ZOLOFT					
Concurrent use of NSAID and SSRI may result in an increased risk of bleeding.					
CARDIOASPIRIN	Maggiore	Non specificato	Discreta	39	21
DICLOFENAC DOC G					
Concurrent use of ASPIRIN and DICLOFENAC may result in increased risk of bleeding.					
CELEBREX	Maggiore	Ritardato	Buona	39	15
COTAREG					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
CELEBREX	Maggiore	Non specificato	Eccellente	39	13
CYMBALTA					
Concurrent use of NSAID and SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS may result in an increased risk of bleeding.					
BRUFEN	Maggiore	Ritardato	Buona	38	24
PRETERAX					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
ALKET	Maggiore	Ritardato	Buona	38	19
MODURETIC					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
ALKET	Maggiore	Non specificato	Buona	38	19
MODURETIC					
Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity.					
DELTACORTENE	Maggiore	Non specificato	Discreta	37	22
INDOXEN					
Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.					
CIPRALEX	Maggiore	Non specificato	Eccellente	37	24

Stat IF per farmaco (limitato alle prime 200 interazioni con maggior numero di occorrenze)

Pag. 6 di 13

Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX®.



	Gravità:	Ins:	Doc.:	Numero:	Ass:
OKI					
Concurrent use of NSAID and SSRI may result in an increased risk of bleeding.					
CLEXANE Maggiore Non specificato Buona 37 28					
DICLOREUM					
Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding.					
DIURESIX Maggiore Non specificato Buona 37 2					
FELDENE					
Concurrent use of LOOP DIURETICS and NSAIDS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
CELEBREX Maggiore Non specificato Discreta 37 10					
SALAZOPYRIN EN					
Concurrent use of NSAIDS and NSAIDS AND SALICYLATES may result in increased risk of bleeding.					
MEDROL Maggiore Non specificato Discreta 36 28					
ORUDIS					
Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.					
DELTACORTENE Maggiore Non specificato Discreta 36 26					
DICLOFENAC DOC G					
Concurrent use of CORTICOSTEROIDS and NSAIDS (SELECTED) may result in increased risk of gastrointestinal ulcer or bleeding.					
CELEBREX Maggiore Non specificato Eccellente 36 17					
LAROXYL					
Concurrent use of NSAID and TRICYCLIC ANTIDEPRESSANTS may result in an increased risk of bleeding.					
ASCRIPPIN Maggiore Non specificato Buona 36 23					
BRUFEN					
Concurrent use of ASPIRIN and IBUPROFEN may result in decreased antiplatelet effect of aspirin and additive risk of bleeding.					
BRUFEN Maggiore Non specificato Eccellente 35 22					
PAROXETINA M.G					
Concurrent use of NSAID and SSRI may result in an increased risk of bleeding.					
BRUFEN Maggiore Ritardato Buona 35 22					
ZOPRAZIDE					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
CARDIOASPIRIN Maggiore Non specificato Discreta 35 24					
FELDENE FAST					
Concurrent use of ASPIRIN and NSAIDS may result in increased risk of bleeding.					
CARDIOASPIRIN Maggiore Non specificato Discreta 35 23					
VOLTFAST					
Concurrent use of ASPIRIN and NSAIDS may result in increased risk of bleeding.					
LAROXYL Maggiore Non specificato Eccellente 35 21					
VOLTAREN					
Concurrent use of NSAID and TRICYCLIC ANTIDEPRESSANTS may result in an increased risk of bleeding.					
INDOXEN Maggiore Non specificato Eccellente 35 19					
LAROXYL					
Concurrent use of NSAID and TRICYCLIC ANTIDEPRESSANTS may result in an increased risk of bleeding.					
CELEBREX Maggiore Ritardato Buona 34 18					
VASORETIC					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
BENTELAN Maggiore Non specificato Discreta 33 25					
VOLTFAST					
Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.					
ACIDO ACETILS EG Maggiore Non specificato Discreta 33 20					
DICLOFENAC EG					
Concurrent use of ASPIRIN and DICLOFENAC may result in increased risk of bleeding.					
INDOXEN Maggiore Ritardato Buona 33 14					
MODURETIC					



	Gravità:	Ins:	Doc.:	Numero:	Ass:
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
BRUFEN	Maggiore	Non specificato	Discreta	33	24
PENTACOL 800					
Concurrent use of NSAIDS and NSAIDS AND SALICYLATES may result in increased risk of bleeding.					
INDOXEN	Maggiore	Non specificato	Discreta	33	14
MODURETIC					
Concurrent use of INDOMETHACIN and POTASSIUM-SPARING DIURETICS may result in increased serum potassium levels or acute renal failure.					
BENTELAN	Maggiore	Non specificato	Discreta	32	25
SYNPLEX FORTE					
Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.					
DICLOREUM	Maggiore	Non specificato	Discreta	32	29
MEDROL					
Concurrent use of CORTICOSTEROIDS and NSAIDS (SELECTED) may result in increased risk of gastrointestinal ulcer or bleeding.					
FELDENE FAST	Maggiore	Ritardato	Buona	32	19
MODURETIC					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
FELDENE FAST	Maggiore	Non specificato	Buona	32	19
MODURETIC					
Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity.					
MEDROL	Maggiore	Non specificato	Discreta	31	21
NAPROSYN					
Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.					
CELEBREX	Maggiore	Non specificato	Eccellente	31	13
SEREUPIN					
Concurrent use of NSAID and SSRI may result in an increased risk of bleeding.					
ACESISTEM	Maggiore	Ritardato	Buona	31	16
BRUFEN					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
ARTROSILENE	Maggiore	Ritardato	Buona	31	20
MODURETIC					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
ARTROSILENE	Maggiore	Non specificato	Buona	31	20
MODURETIC					
Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity.					
BRUFEN	Maggiore	Ritardato	Buona	30	18
PERINDOPRIL IND.M.G.					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
LAROXYL	Maggiore	Non specificato	Eccellente	30	22
ORUDIS					
Concurrent use of NSAID and TRICYCLIC ANTIDEPRESSANTS may result in an increased risk of bleeding.					
DELTACORTENE	Maggiore	Non specificato	Discreta	29	16
NAPROSYN					
Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.					
LODOZ	Maggiore	Ritardato	Buona	29	19
OKI					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
CELEBREX	Maggiore	Non specificato	Discreta	28	5

Stat. IF per farmaco (limitato alle prime 200 interazioni con maggior numero di occorrenze)

Pag. 8 di 13

Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX®.



Gravità:	Ins:	Doc.:	Numero:	Ass:
----------	------	-------	---------	------

URBASON

Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.

DICLOFENAC EG	Maggiore	Non specificato	Discreta	28	14
----------------------	----------	-----------------	----------	----	----

MEDROL

Concurrent use of CORTICOSTEROIDS and NSAIDS (SELECTED) may result in increased risk of gastrointestinal ulcer or bleeding.

CLEXANE	Maggiore	Non specificato	Buona	28	20
----------------	----------	-----------------	-------	----	----

KETOPROFENE EG

Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding.

CELEBREX	Maggiore	Ritardato	Buona	28	11
-----------------	----------	-----------	-------	----	----

KARVEZIDE

Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.

OLPREZIDE	Maggiore	Ritardato	Buona	28	18
------------------	----------	-----------	-------	----	----

TORADOL

Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.

KARVEZIDE	Maggiore	Ritardato	Buona	28	20
------------------	----------	-----------	-------	----	----

OKI

Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.

MOBIC 15	Maggiore	Ritardato	Buona	28	12
-----------------	----------	-----------	-------	----	----

MODURETIC

Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.

MOBIC 15	Maggiore	Non specificato	Buona	28	12
-----------------	----------	-----------------	-------	----	----

MODURETIC

Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity.

DELTACORTENE	Maggiore	Non specificato	Discreta	27	23
---------------------	----------	-----------------	----------	----	----

SYNFLEX FORTE

Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.

BRUFEN	Maggiore	Non specificato	Eccellente	27	9
---------------	----------	-----------------	------------	----	---

ELOPRAM

Concurrent use of NSAID and SSRI may result in an increased risk of bleeding.

DICLOREUM	Maggiore	Ritardato	Buona	27	19
------------------	----------	-----------	-------	----	----

VASORETIC

Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.

BIFRIZIDE	Maggiore	Ritardato	Buona	27	15
------------------	----------	-----------	-------	----	----

DICLOREUM

Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.

ARTROSILENE	Maggiore	Ritardato	Buona	27	6
--------------------	----------	-----------	-------	----	---

ZESTORETIC

Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.

ORUDIS	Maggiore	Ritardato	Buona	27	18
---------------	----------	-----------	-------	----	----

TRIATEC HCT

Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.

DICLOREUM	Controindicato	Nelle 24 ore	Discreta	27	20
------------------	----------------	--------------	----------	----	----

TORADOL

La contemporanea assunzione di KETOROLAC e AGENTI ANTIINFIAMMATORI NON STEROIDEI può portare ad effetti avversi gastrointestinali seri (ulcere peptiche, emorragia e/o perforazione gastrointestinale).

BRUFEN	Maggiore	Non specificato	Discreta	27	16
---------------	----------	-----------------	----------	----	----

TICLOPIDINA M.G.

Concurrent use of ANTIPLATELET AGENTS and NSAIDS may result in increased risk of bleeding.

Stat IF per farmaco (limitato alle prime 200 interazioni con maggior numero di occorrenze)	Pag. 9 di 13
--	--------------

Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX®.



	Gravità:	Ins:	Doc.:	Numero:	Ass:
COUMADIN	Maggiore	Non specificato	Discreta	27	19
VOLTAREN					
Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding.					
OKI	Maggiore	Ritardato	Buona	27	15
REUMAFLEX					
La contemporanea assunzione di KETOPROFENE e METOTREXATO può determinare tossicità da metotrexato (leucopenia, trombocitopenia, anemia, nefrotossicità, ulcerazioni della mucosa).					
BRUFEN	Maggiore	Ritardato	Eccellente	26	6
SANDIMMUN NEORAL					
L'uso concomitante di farmaci antinfiammatori non steroidei e ciclosporina può portare ad un aumento del rischio di nefrotossicità da ciclosporina.					
ARTROSILENE	Maggiore	Non specificato	Discreta	26	21
DELTACORTENE					
Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.					
BRUFEN	Maggiore	Non specificato	Eccellente	26	15
SERTRALINA M.G.					
Concurrent use of NSAID and SSRI may result in an increased risk of bleeding.					
BRUFEN	Maggiore	Non specificato	Eccellente	26	22
PAROXETINA EG					
Concurrent use of NSAID and SSRI may result in an increased risk of bleeding.					
DELTACORTENE	Maggiore	Non specificato	Discreta	26	21
VOLTFAST					
Concurrent use of CORTICOSTEROIDS and NSAIDS (SELECTED) may result in increased risk of gastrointestinal ulcer or bleeding.					
CARDIRENE	Maggiore	Non specificato	Discreta	26	10
VOLTAREN					
Concurrent use of ASPIRIN and DICLOFENAC may result in increased risk of bleeding.					
CELEBREX	Maggiore	Non specificato	Discreta	26	20
VOLTAREN					
Concurrent use of DICLOFENAC and NSAIDS AND SALICYLATES may result in increased risk of bleeding.					
CLEXANE	Maggiore	Non specificato	Buona	26	11
IBUPROFENE DOC G					
Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding.					
CELEBREX	Maggiore	Ritardato	Buona	26	14
MICARDISPLUS					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
COUMADIN	Maggiore	Non specificato	Discreta	26	11
DICLOREUM					
Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding.					
FUROSEMIDE DOC	Maggiore	Non specificato	Buona	26	15
TORadol					
Concurrent use of LOOP DIURETICS and NSAIDS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
FELDENE	Maggiore	Non specificato	Discreta	26	25
OKI					
Concurrent use of NSAIDS and NSAIDS AND SALICYLATES may result in increased risk of bleeding.					
CELEBREX	Maggiore	Non specificato	Discreta	25	10
SYMBICORT					
Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.					
INDOXEN	Maggiore	Non specificato	Discreta	25	10
MEDROL					
Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.					
CELEBREX	Maggiore	Non specificato	Eccellente	25	11
CIPRALEX					
Concurrent use of NSAID and SSRI may result in an increased risk of bleeding.					
DAPAROX	Maggiore	Non specificato	Eccellente	25	4

Stat IF per farmaco (limitato alle prime 200 interazioni con maggior numero di occorrenze)

Pag. 10 di 13

Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX®.



	Gravità:	Ins:	Doc.:	Numero:	Ass:
FELDENE					
Concurrent use of NSAID and SSRI may result in an increased risk of bleeding.					
CLEXANE T					
	Maggiore	Non specificato	Buona	25	6
IBUPROFENE DOC G					
Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding.					
BRUFEN					
	Maggiore	Ritardato	Buona	25	8
PRELECTAL					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
FELDENE FAST					
	Maggiore	Ritardato	Buona	25	11
TRIATEC HCT					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
OKI					
	Maggiore	Non specificato	Discreta	25	16
TICLOPIDINA DOROM					
Concurrent use of ANTIPLATELET AGENTS and NSAIDS may result in increased risk of bleeding.					
BRUFEN					
	Maggiore	Non specificato	Discreta	25	15
TIKLID					
Concurrent use of ANTIPLATELET AGENTS and NSAIDS may result in increased risk of bleeding.					
ORUDIS					
	Controindicato	Nelle 24 ore	Discreta	25	16
TORADOL					
Concurrent use of KETOROLAC and NSAIDS may result in enhanced gastrointestinal adverse effects (peptic ulcers, gastrointestinal bleeding and/or perforation).					
DICLOREUM					
	Maggiore	Non specificato	Eccellente	25	19
LAROXYL					
Concurrent use of NSAID and TRICYCLIC ANTIDEPRESSANTS may result in an increased risk of bleeding.					
ARTROTEC					
	Maggiore	Non specificato	Discreta	25	6
CARDIOASPIRIN					
Concurrent use of ASPIRIN and NSAIDS may result in increased risk of bleeding.					
BENTELAN					
	Maggiore	Non specificato	Discreta	24	20
MOBIC 15					
Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.					
DELTACORTENE					
	Maggiore	Non specificato	Discreta	24	13
DICLOFENAC M.G.					
Concurrent use of CORTICOSTEROIDS and NSAIDS (SELECTED) may result in increased risk of gastrointestinal ulcer or bleeding.					
CLEXANE					
	Maggiore	Non specificato	Buona	24	16
IBUPROFENE ALTER					
Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding.					
DICLOREUM					
	Maggiore	Ritardato	Buona	24	10
ENALAPRIL ID.EG					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
DICLOFENAC EG					
	Maggiore	Ritardato	Buona	24	5
VASORETIC					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
MOBIC 15					
	Maggiore	Ritardato	Buona	24	8
TRIATEC HCT					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
COUMADIN					
	Maggiore	Non specificato	Discreta	24	19
TORADOL					
Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding.					
COUMADIN					
	Maggiore	Non specificato	Discreta	24	11
IBUPROFENE DOC G					
Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding.					



	Gravità:	Ins:	Doc.:	Numero:	Ass:
EFEXOR	Maggiore	Non specificato	Eccellente	24	10
OKI					
Concurrent use of NSAID and SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS may result in an increased risk of bleeding.					
BRUFEN	Maggiore	Non specificato	Discreta	24	20
SYNPLEX FORTE					
Concurrent use of NSAIDS and NSAIDS AND SALICYLATES may result in increased risk of bleeding.					
CELEBREX	Maggiore	Non specificato	Discreta	24	11
LANOXIN					
Concurrent use of CELECOXIB and DIGOXIN may result in increased serum concentration and half-life of digoxin.					
CELECOXIB TEVA	Maggiore	Non specificato	Discreta	23	16
MEDROL					
Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.					
OKI	Maggiore	Non specificato	Discreta	23	17
SYMBICORT					
Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.					
BLOPRESID	Maggiore	Ritardato	Buona	23	11
VOLTAREN					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
CELEBREX	Maggiore	Ritardato	Buona	23	15
OLPREZIDE					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
CELEBREX	Maggiore	Non specificato	Discreta	23	10
TICLOPIDINA DOROM					
Concurrent use of ANTIPLATELET AGENTS and NSAIDS may result in increased risk of bleeding.					
COUMADIN	Maggiore	Non specificato	Discreta	23	17
IBUPROFENE ALTER					
Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding.					
LASIX	Maggiore	Non specificato	Buona	23	13
MOBIC 15					
Concurrent use of LOOP DIURETICS and NSAIDS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
INDOXEN	Maggiore	Ritardato	Buona	23	7
METHOTREXATE					
L'utilizzo concomitante di indometacina e metotrexato può causare tossicità da metotrexato (leucopenia, trombocitopenia, anemia, nefrotossicità, ulcere mucosali)					
BENTELAN	Maggiore	Non specificato	Discreta	22	13
INDOXEN					
Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding.					
SEREUPIN	Maggiore	Non specificato	Eccellente	22	13
VOLTAREN					
Concurrent use of NSAID and SSRI may result in an increased risk of bleeding.					
CIPRALEX	Maggiore	Non specificato	Eccellente	22	9
TORADOL					
Concurrent use of NSAID and SSRI may result in an increased risk of bleeding.					
BIFRIZIDE	Maggiore	Ritardato	Buona	22	13
OKI					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
BIFRIZIDE	Maggiore	Ritardato	Buona	22	9
CELEBREX					
Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.					
BRUFEN	Maggiore	Ritardato	Buona	22	13
OLMEGAN					



Gravità:	Ins:	Doc.:	Numero:	Ass:
----------	------	-------	---------	------

Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.

CELEBREX	Maggiore	Ritardato	Buona	22	13
-----------------	----------	-----------	-------	----	----

Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity.

CARDIOASPIRIN	Maggiore	Non specificato	Discreta	22	17
----------------------	----------	-----------------	----------	----	----

Concurrent use of ASPIRIN and NSAIDS may result in increased risk of bleeding.

LASIX	Maggiore	Non specificato	Buona	22	6
--------------	----------	-----------------	-------	----	---

WALIX	Maggiore	Non specificato	Eccellente	22	10
--------------	----------	-----------------	------------	----	----

Concurrent use of LOOP DIURETICS and NSAIDS may result in reduced diuretic effectiveness and possible nephrotoxicity.

CYMBALTA	Maggiore	Non specificato	Eccellente	22	10
-----------------	----------	-----------------	------------	----	----

ORUDIS					
---------------	--	--	--	--	--

Concurrent use of NSAID and SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS may result in an increased risk of bleeding.